Ifosfamide is an alkylating agent with well-demonstrated efficacy against a large number of malignant diseases. With cyclophosphamide it shares a toxicity profile characterized by myelosuppression and urotoxicity, but ifosfamide has additionally disclosed adverse neurological effects. Ifosfamide-related central nervous system toxicity is characterized by metabolic encephalopathy of varying severity. Symptoms have been reported in 5–30% of all patients treated with ifosfamide. The mechanism of ifosfamide-related central nervous system toxicity has not been fully elucidated, although the symptoms have most often been noted when the drug is given at high doses or administered orally. The neurotoxicity is generally self-limiting and reversible between 48 and 72 h after discontinuation of ifosfamide, although fatal sequelae have been reported. Therapeutic options are now available.

Keywords:
Ifosfamide, Neurotoxicity, Toxic encephalopathy
1.
Cerny T, Margison JM, Thatcher N, Wilkinson PM: Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol 1986;18:261–264.
2.
Wagner T, Drings P: Pharmacokinetics and bioavailability of oral ifosfamide. Arzneimittelforschung 1986;36:878–880.
3.
Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989;49:753–757.
4.
Lind MJ, Roberts HL, Thatcher N, Idle JR: The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 1990;26:105–111.
5.
Manegold C, Bischoff H, Fischer JR, Lochner S, Peukert M, Schmahl A, Drings P: Oral ifosfamide-mesna: A clinical investigation in advanced non-small-cell lung cancer. Ann Oncol 1992;3:723–726.
6.
Cohen MH, Creaven PJ, Tejada F, Hansen HH, Muggia F, Mittelman A, Selawry OS: Phase I clinical trial of isophosphamide (NSC-109724). Cancer Chemother Rep 1975;59:751–755.
7.
Patel SR, Forman AD, Benjamin RS: High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst 1994;86:305–306.
8.
Frisk P, Stalberg E, Stromberg B, Jakobson A: Painful peripheral neuropathy after treatment with high-dose ifosfamide. Med Pediatr Oncol 2001;37:379–382.
9.
Pinkerton CR, Rogers H, James C, Bowman A, Barbor PR, Eden OB, Pritchard J: A phase II study of ifosfamide in children with recurrent solid tumours. Cancer Chemother Pharmacol 1985;15:258–262.
10.
Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G: Unexpected toxicity in patients treated with iphosphamide. Cancer Res 1972;32:921–924.
11.
Sparr SA. Ifosfamide; in Spencer PS, Schaumburg HH (eds): Experimental and Clinical Neurotoxicology, ed 2. New York, Oxford University Press, 2000, pp 675–677.
12.
Meanwell CA, Blake AE, Latief TN, Blackledge G, Mould JJ, Blake DR, Shaw IC, Honigsberger L, Spooner D, Williams AC et al: Encephalopathy associated with ifosphamide/mesna therapy. Lancet 1985;i:406–407.
13.
Bremner DN, McCormick JS, Thomson JW: Clinical trial of isophosphamide (NSC- 109724) – Results and side effects. Cancer Chemother Rep 1974;58:889–893.
14.
Wang JJ, Mittelman A, Twetrinon P: Clinical trial of iphosphamide. Proc Am Assoc Cancer Res and ASCO 1974;15:110.
15.
Salloum E, Flamant F, Ghosn M, Taleb N, Akatchereian C: Irreversible encephalopathy with ifosfamide/mesna. J Clin Oncol 1987;5:1303–1304.
16.
Merimsky O, Reider-Groswasser I, Wigler N, Chaitchik S: Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand 1992;86:521–525.
17.
DiMaggio JR, Brown R, Baile WF, Schapira D: Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994;73:1509–1514.
18.
Heim ME, Fiene R, Schick E, Wolpert E, Queisser W: Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 1981;100:113–116.
19.
Pratt CB, Green AA, Horowitz ME, Meyer WH, Etcubanas E, Douglass E, Hayes FA, Thompson E, Wilimas J, Igarashi M et al: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986;4:1253–1261.
20.
Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst 1988;80:556–566.
21.
Anderson NR, Tandon DS: Ifosfamide extrapyramidal neurotoxicity. Cancer 1991;68:72–75.
22.
Vokes EE, Hoffman PC: CNS Toxicity during Ifosfamide-Based Chemotherapy. Princeton, Bristol-Meyers Squibb Co, 1996.
23.
Meyer T, Ludolph AC, Munch C: Ifosfamide encephalopathy presenting with asterixis. J Neurol Sci 2002;199:85–88.
24.
Wengs WJ, Talwar D, Bernard J: Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol 1993;50:1104–1105.
25.
Primavera A, Audenino D, Cocito L: Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci 2002;29:180–183.
26.
Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G: Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;22:815–819.
27.
Simonian NA, Gilliam FG, Chiappa KH: Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology 1993;43:2700–2702.
28.
Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD: Gynecologic Oncology Group experience with ifosfamide. Semin Oncol 1990;17(suppl 4):6–10.
29.
Cantwell BM, Idle M, Millward MJ, Hall G, Lind MJ: Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion. Ann Oncol 1990;1:232.
30.
Bruggers CS, Friedman HS, Tien R, Delong R: Cerebral atrophy in an infant following treatment with ifosfamide. Med Pediatr Oncol 1994;23:380–383.
31.
Shuper A, Stein J, Goshen J, Kornreich L, Yaniv I, Cohen IJ: Subacute central nervous system degeneration in a child: An unusual manifestation of ifosfamide intoxication. J Child Neurol 2000;15:481–483.
32.
Norpoth K: Studies on the metabolism of isopnosphamide (NSC-109724) in man. Cancer Treat Rep 1976;60:437–443.
33.
Goren MP, Wright RK, Pratt CB, Pell FE: Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986;ii:1219–1220.
34.
Aeschlimann C, Kupfer A, Schefer H, Cerny T: Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos 1998;26:883–890.
35.
Nelson RL, Creaven PJ, Cohen MH, Fossieck BE Jr: Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724). Eur J Cancer 1976;12:195–198.
36.
Rodriguez V, Bodey GP, Freireich EJ, McCredie KB, McKelvey EM, Tashima CK: Reduction of ifosfamide toxicity using dose fractionation. Cancer Res 1976;36:2945–2948.
37.
Klein HO, Wickramanayake PD, Coerper C, Christian E, Pohl J, Brock N: High-dose ifosfamide and mesna as continuous infusion over five days – A phase I/II trial. Cancer Treat Rev 1983;10(suppl A):167–173.
38.
Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, Wilimas JA, Hayes FA, Green AA: Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987;71:131–135.
39.
Perren TJ, Turner RC, Smith IE: Encephalopathy with rapid infusion ifosfamide/mesna. Lancet 1987;i:390–391.
40.
Antman KH, Elias A, Ryan L: Ifosfamide and mesna: Response and toxicity at standard- and high-dose schedules. Semin Oncol 1990;17(suppl 4):68–73.
41.
Kamen BA, Frenkel E, Colvin OM: Ifosfamide: Should the honeymoon be over? J Clin Oncol 1995;13:307–309.
42.
Kupfer A, Aeschlimann C, Wermuth B, Cerny T: Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 1994;343:763–764.
43.
Kupfer A, Aeschlimann C, Cerny T: Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996;50:249–252.
44.
Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson AD, Beaune PH et al: Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994;47:1157–1163.
45.
Bagley CM Jr, Bostick FW, DeVita VT Jr: Clinical pharmacology of cyclophosphamide. Cancer Res 1973;33:226–233.
46.
Colvin M: The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 1982;9(suppl 1):2–7.
47.
Kurowski V, Cerny T, Kupfer A, Wagner T: Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 1991;117(suppl 4):148–153.
48.
Issels RD, Meier TH, Muller E, Multhoff G, Wilmanns W: Ifosfamide induced stress response in human lymphocytes. Mol Aspects Med 1993;14:281–286.
49.
Sood C, O’Brien PJ: Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 1993;46:1621–1626.
50.
Sood C, O’Brien PJ: Chloroacetaldehyde-induced hepatocyte cytotoxicity. Mechanisms for cytoprotection. Biochem Pharmacol 1994;48:1025–1032.
51.
Sood C, O’Brien P: J 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity. Br J Cancer Suppl 1996;27:S287–S293.
52.
Lauterburg BH, Nguyen T, Hartmann B, Junker E, Kupfer A, Cerny T: Depletion of total cysteine, glutathione and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 1994;35:132–136.
53.
Visarius TM, Stucki JW, Lauterburg BH: Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett 1997;412:157–160.
54.
Visarius TM, Stucki JW, Lauterburg BH: Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther 1999;289:820–824.
55.
Hofmann U, Eichelbaum M, Seefried S, Meese CO: Identification of thiodiglycolic acid, thiodiglycolic acid sulfoxide and (3-carboxymethylthio)lactic acid as major human biotransformation products of S-carboxymethyl-L-cysteine. Drug Metab Dispos 1991;19:222–226.
56.
Visarius TM, Bahler H, Kupfer A, Cerny T, Lauterburg BH: Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos 1998;26:193–196
57.
Peters RA: Lethal synthesis. Proc R Soc Lond (B) 1952;139:143–170.
58.
Chatton JY, Idle JR, Vagbo CB, Magistretti PJ: Insights into the mechanisms of ifosfamide encephalopathy: Drug metabolites have agonistic effects on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate receptors and induce cellular acidification in mouse cortical neurons. J Pharmacol Exp Ther 2001;299:1161–1168.
59.
Goodman SI, Frerman FE: Glutaric acidemia type II and defects of the mitochondrial respiratory chain; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, ed 6. New York, McGraw-Hill, 1989, vol 1, pp 915–931.
60.
Aeschlimann C, Cerny T, Küpfer A: Chloroethylamine: A urinary metabolite of patients with high-dose ifosfamide treatment. Naunyn Schmiedebergs Arch Pharmacol 1994;349:R130.
61.
Highley MS, Momerency G, Van Cauwenberghe K, Van Oosterom AT, de Bruijn EA, Maes RA, Blake P, Mansi J, Harper PG: Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. Drug Metab Dispos 1995;23:433–437.
62.
Cavallini D, Ricci G, Dupre S, Pecci L, Costa M, Matarese RM, Pensa B, Antonucci A, Solinas SP, Fontana M: Sulfur-containing cyclic ketimines and imino acids. A novel family of endogenous products in the search for a role. Eur J Biochem 1991;202:217–223.
63.
Ricci G, Nardini M, Caccuri AM, Federici G: Interaction between 1,4-thiazine derivatives and D-amino-acid oxidase. Biochim Biophys Acta 1983;748:40–47.
64.
Harpey JP, Charpentier C, Coude M: Methylene blue for riboflavin-unresponsive glutaricaciduria type II. Lancet 1986;i:391.
65.
Zulian GB, Tullen E, Maton B: Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med 1995;332:1239–1240.
66.
Ferrero JM, Eftekari P, Largillier R, Dreyfus G, Namer M: Treatment of ifosfamide-induced encephalopathy with methylene blue. Bull Cancer 1995;82:598–599.
67.
Alonso JL, Nieto Y, Lopez JA, Martin M, Diaz-Rubio E: Ifosfamide encephalopathy and methylene blue: A case report. Ann Oncol 1996;7:643–644.
68.
Cerny T, Lind M, Thatcher N, Swindell R, Stout R: A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer. Br J Cancer 1989;60:258–261.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.